液体栓塞剂治疗I型内漏的系统综述
本系统综述纳入10项研究共194例EVAR术后I型内漏患者,评估液体栓塞剂单药治疗的安全性和有效性。技术成功率为97.9%,临床成功率为87.6%,中位随访仅13.0个月,长期数据缺乏。栓塞后二次破裂风险约2.1%,均发生于初始治疗直径超过70 mm的动脉瘤。
要点
- 液体栓塞剂治疗EVAR术后I型内漏技术成功率高(97.9%)。
- 中位随访13.0个月,临床成功率87.6%,长期疗效数据缺乏。
- 二次破裂发生率2.1%,均见于初始直径超过70 mm的动脉瘤。
核心结论
- 液体栓塞剂治疗I型内漏初始技术成功率高,但长期临床成功率数据缺乏。
- 中位随访13个月下二次破裂风险约2%,与未治疗的I型内漏相当,无论栓塞是否初始成功。
- 总体未显示EVAR术后I型内漏栓塞可降低二次动脉瘤破裂风险。
研究设计与样本
- 系统综述,检索报告液体栓塞剂单药治疗EVAR术后I型内漏的所有研究。
- 从1604篇文章中纳入10项研究,共194例患者接受液体栓塞剂治疗。
- 患者中男性占73.2%,中位年龄71岁。
主要发现
- 总体技术成功率为97.9%。
- 临床成功率为87.6%。
- 中位随访仅13.0个月(范围1-89个月),长期成功数据几乎缺失。
- 报告4例(2.1%)栓塞后因内漏复发导致的二次动脉瘤破裂,均发生于初始治疗直径超过70 mm的动脉瘤。
临床怎么用
- 液体栓塞剂可作为EVAR术后I型内漏的二次干预选择之一,初始技术成功率高。
- 对初始治疗直径超过70 mm的动脉瘤,栓塞后仍需警惕二次破裂风险。
- 因长期数据缺乏,栓塞后需密切随访监测内漏复发和动脉瘤破裂。
局限性
- 中位随访仅13.0个月,长期临床成功数据几乎缺失。
- 纳入研究数量有限(10项),样本量194例。
- 二次破裂风险与未治疗I型内漏相当,但晚期栓塞的结果存在争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The long-term success of endovascular aneurysm repair (EVAR) is limited by complications, most importantly endoleaks. In case of (persistent) type I endoleak (T1EL), secondary intervention is indicated to prevent secondary aneurysm rupture. Different treatment options are suggested for T1ELs, such as endo anchors, (fenestrated) cuffs, embolization, or open conversion. Currently, the treatment of T1EL with liquid embolic agents is available; however, results are not yet addressed. This review presents the safety and efficacy of embolization with liquid embolic agents for treatment of T1ELs after EVAR. METHODS: A systematic literature search was performed for all studies reporting the use of liquid embolic agents as monotherapy for treatment of T1ELs after EVAR. Patient numbers, technical success (successful delivery of liquid embolics in the T1EL) and clinical success (absence of aneurysm related death, endoleak recurrence or additional interventions during follow-up) were examined. RESULTS: Of 1604 articles, 10 studies met the selection criteria, including 194 patients treated with liquid embolics; 73.2% of the patients were male with a median age of 71 years. The overall technical success was 97.9%. Clinical success was 87.6%. Because the median follow-up was only 13.0 months (range, 1-89 months), data on long-term success are almost absent. Four cases (2.1%) of secondary aneurysm rupture after embolization owing to endoleak recurrence were reported. All ruptures occurred in aneurysms exceeding initial treatment diameter of 70 mm. CONCLUSIONS: Initial technical success after liquid embolization for T1EL is high, although long-term clinical success rates are lacking. Within this review, the risk of secondary rupture is comparable with untreated T1EL at 2% with a median follow-up of 13 months, regardless of the initial success of embolization. In general, no decrease in secondary aneurysm rupture after embolization of T1EL after EVAR is demonstrated, although the results of late embolization are debated.
引用
- van Schaik TG, Meekel JP, Hoksbergen AWJ, et al. Systematic review of embolization of type I endoleaks using liquid embolic agents. J Vasc Surg. 2021. PMID: 33940072. doi:10.1016/j.jvs.2021.03.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。